Lazaros J. Lekakis, MD
CAR T-cell therapy has brought newfound hope to patients with relapsed acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), where the outlook had traditionally been bleak, said Lazaros J. Lekakis, MD.
In patients with DLBCL, the CD19-directed CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) has not only generated excitement in the clinical trial space, but recent data have suggested the benefit is expanding in the real-world setting. Early results of a real-world population study demonstrated a median progression-free survival (PFS) of 6.18 months—in the ZUMA-1 trial, median PFS was 5.8 months.1
The overall response rate was 79% by day 30 post-infusion and 82% overall.
In ALL, the CD19-targeted product tisagenlecleucel (Kymriah) garnered attention for its encouraging data in the ELIANA study. In updated data presented at the 2018 ASH Annual Meeting, the 2-year relapse-free survival rate with the therapy was 62%.2
... to read the full story